Dynomics

Precision cardiac therapies to target heart function.

[Dynomics @dynomics_]

Research in @NEJM + @jclinicalinvest from @PennMedicine provides insight into peripartum cardiomyopathy + dilated cardiomyopathy, rare heart conditions.

Advancing such research leads to necessary progress where knowledge gaps exist.

Via @medical_xpress: https://t.co/3srjz7uZ93

[Dynomics @dynomics_]

In vivo base editing in humans may actually work, according to the latest data released by @VerveTx. But, after identifying potential safety concerns, investors aren’t totally convinced.

Read more about the latest Verve data in @FierceBiotech: https://t.co/5XsvEw2gM1

[Dynomics @dynomics_]

Biotech gene therapy shop, LEXEO Therapeutics recently announced and closed a $100M IPO.

The company will use the funds to scale its main therapeutics, including its Alzheimer’s candidate being assessed for arrhythmogenic cardiomyopathy.

More @biospace: https://t.co/noFnCm0MLo

[Dynomics @dynomics_]

Last week, a deal was struck between @EliLillyandCo and @BeamTx.

Lilly will pay $200M for Beam’s stake in @VerveTx, a gene-editing company developing therapeutics to address cardiovascular disease.

More via @matthewherper @statnews: https://t.co/qbgNI2gwIn

[Dynomics @dynomics_]

Tech is a game-changer when it comes to healthcare.

Last week, @anumanainc + @MayoClinic received @US_FDA clearance for their AI model that can identify signs of low ejection fraction (LEF) in ECGs.

Learn more via @byMichaelWalter @CardioBusiness: https://t.co/MclWGU4Hf1

[Dynomics @dynomics_]

In recognition of #WorldHeartDay today, we’re taking it back to last month when our CEO, Drew Titmarsh, spoke to host @njlittman on the @biovergehq podcast.

Check out the full episode: https://t.co/EjLJeTS59k

[Dynomics @dynomics_]

In May, the @WHO released new guidance to reduce the use of #artificialsweeteners due to their link to increased #cardiovascular disease + type 2 diabetes.

A recent article in @NEJM rounds up several studies explaining the impact of non-sugar sweeteners: https://t.co/h7d1RZfYc3

[Dynomics @dynomics_]

Now 3 years post-pandemic, scientists can better see how #COVID19 impacts our #hearthealth 🩺

Their leading theory? The virus stimulates widespread inflammation, increasing the risk of #heartattacks and #strokes.

More via @SmithDanaG @nytimes: https://t.co/q037jrmfij

[Dynomics @dynomics_]

Did you miss our CEO’s guest appearance on @biovergehq podcast last week?

He spoke to host @njlittman about the future of #cardiovascular therapeutics, the #techbio vs #biotech debate, the culture at Dynomics, and more!

Check it out: https://t.co/keXM9LeZXb

[Dynomics @dynomics_]

A @novonordisk trial found #Wegovy can reduce the risk of #cardiovascular events by 20% in non-diabetic adults.

The study could improve #insurance coverage for the drug once further peer-reviewed + published in a medical journal.

Via @megtirrell @CNN: https://t.co/2OLRGSCV8J

[Dynomics @dynomics_]

The #RNAi-#cardiovascular scientific community has recently seen the announcement of two impressive collabs: @Alnylam-@Roche and @ionispharma-@Novartis.

Each uses RNAi technology to treat CVD and related risks.

Alnylam:
https://t.co/AxW3vhUQUZ

Ionis: https://t.co/LKgjkaPGYs

[Dynomics @dynomics_]

The $60M research collab from @VerveTx + @EliLillyandCo, plus a new agreement between @AlexionPharma + @Pfizer, points to a promising future for #CVD-related #genomic medicine research.

Learn more about Verve:
https://t.co/kZ89jArBaR

And about Alexion:
https://t.co/GdwxYdCKAA

[Dynomics @dynomics_]

A new global study published in @NEJM found that statins can reduce the risk of #cardiovascular disease in people living with #HIV.

The findings can change how doctors treat HIV+ patients with cardiovascular risks.

Read more via @djbulbaczar @statnews: https://t.co/GVXW1Ibdgn

[Dynomics @dynomics_]

The @US_FDA has approved the first drug to enter clinical trials based on efficacy data from #organoids - a breakthrough for rare disease research and treatment potential! #biotech

More about the approval in @BioWorld: https://t.co/7jstevGdW9

[Dynomics @dynomics_]

Research presented at this year’s @AmDiabetesAssn meeting found that bempedoic acid can be taken as a statin alternative to reduce the risk of major #cardiovascular events.

More via @NBCNews: https://t.co/3hQ0aJQ5Dv

[Dynomics @dynomics_]

#FDA approves first-ever anti-inflammatory drug addressing #cardiovascular risks.

Previously, colchicine was used to treat gout + pericarditis. This now lower dosage is suitable for long-term use in people w/ atherosclerotic #heartdisease.

Via @Medscape: https://t.co/zfsOX5wldT

[Dynomics @dynomics_]

@RocketPharma earned @EMA_News' PRIME designation for its Danon Disease gene therapy (dubbed RP-A501) ✨

RP-A501 showed positive safety + efficacy data in its Phase 1 clinical trial on patients with Danon Disease, a fatal inherited cardiomyopathy.

More: https://t.co/Hz6m84T3l5

[Dynomics @dynomics_]

A study in @JAMA_current found 12 key symptoms to reliably classify someone with long COVID.

With some studies linking COVID to higher cardiovascular risk, understanding the disease better helps scientists address heart health.

Via @ReporterGoodman @CNN: https://t.co/pKZ7daLaIk

[Dynomics @dynomics_]

A new study published in @CellReports may have identified a solution to the life-threatening #arrhythmias caused by attempts to repair a damaged #heart with cell transplants.

More about the incredible discovery via @majohnso @washingtonpost: https://t.co/Kqe3JpeIsb

CC: @UWISCRM

[Dynomics @dynomics_]

Our co-founder, @PorrelloER, recently presented a seminar at @reNEW_Global, about the impact that cardiac maturation can have on disease modeling, drug discovery and regenerative medicine.

Dive into his team’s latest research published in @CellReports: https://t.co/5a93BUCJa7